Not applicableUnknownNCT05288569What this trial is testingIrAE Prediction of Anti-PD-1/L1 in Lung CancerWho this might be right forImmune Checkpoint InhibitorsLung Cancer Peking Union Medical College Hospital 120
Not applicableLooking for participantsNCT05700565What this trial is testingTreatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in ImmunophenotypeWho this might be right forImmune-related Adverse Event Lucie Heinzerling 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04305145What this trial is testingInfliximab for Treatment of Immune Checkpoint Inhibitor ColitisWho this might be right forMelanoma Stage IIIMelanoma Stage IVSkin Cancer Stage III+4 more Massachusetts General Hospital 42
Not applicableStudy completedNCT04960059What this trial is testingNOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNtsWho this might be right forCancerMetastatic MelanomaRenal Cell Carcinoma+1 more The Christie NHS Foundation Trust 24
Not applicableStudy completedNCT06247865What this trial is testingBIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAEWho this might be right forNeoplasms Portsmouth Hospitals NHS Trust 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07381634What this trial is testingThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related ToxicitiesWho this might be right forHepatocellular Carcinoma (HCC)IrAE First Affiliated Hospital of Wenzhou Medical University 134
Not applicableStudy completedNCT03948724What this trial is testingImpact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in OncologyWho this might be right forTherapeutic Patient EducationImmune Checkpoint InhibitorsMelanoma+4 more Institut Cancerologie de l'Ouest 411
Testing effectiveness (Phase 2)Looking for participantsNCT06470971What this trial is testingSiltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialWho this might be right forAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm Yuanquan Yang 40
Testing effectiveness (Phase 2)WithdrawnNCT04060407What this trial is testingCD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)Who this might be right forMetastatic Melanoma Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Testing effectiveness (Phase 2)Looking for participantsNCT06037811What this trial is testingEarly Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory ArthritisWho this might be right forInflammatory ArthritisImmune-related Adverse Event Tom Appleton 30
Testing effectiveness (Phase 2)Looking for participantsNCT05663775What this trial is testingProphylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)Who this might be right forImmune-related Adverse EventDiarrheaAdvanced Melanoma+1 more AHS Cancer Control Alberta 20
Not applicableActive Not RecruitingNCT03409016What this trial is testingBiomarkers of Immune-Related ToxicityWho this might be right forCancerMetastatic Cancer University of Colorado, Denver 69
Post-approval studies (Phase 4)Not Yet RecruitingNCT06785974What this trial is testingStatins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosisWho this might be right forAtherosclerosisMelanomaImmune-related Adverse Event Erasmus Medical Center 140
Not applicableStudy completedNCT05450367What this trial is testingPredictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.Who this might be right forBlood Cancer Assistance Publique - Hôpitaux de Paris 249
Not applicableLooking for participantsNCT05813418What this trial is testingIdentification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) TreatmentWho this might be right forImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more Centre Hospitalier Universitaire, Amiens 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07313202What this trial is testingIvarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceWho this might be right forPatients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE Fujian Cancer Hospital 72
Not applicableEnrolling By InvitationNCT07499128What this trial is testingContinuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventWho this might be right forCytokine Release SyndromeNeoplasmsLymphoma+13 more National Cancer Institute (NCI) 136
Testing effectiveness (Phase 2)Looking for participantsNCT06860542What this trial is testingInhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor PneumonitisWho this might be right forPneumonitisImmune-related Adverse Event AHS Cancer Control Alberta 94
Not applicableStudy completedNCT05544292What this trial is testingRheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point InhibitorsWho this might be right forImmune-related Adverse Event Diakonhjemmet Hospital 69
Not applicableLooking for participantsNCT05799898What this trial is testingFast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint InhibitorsWho this might be right forCancerImmune Checkpoint InhibitorCardiovascular Complication+1 more Institut Mutualiste Montsouris 200